Arimoclomol TFEB Activation for Lysosomal Cholesterol Removal in NPC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no FDA-approved disease-modifying therapies for Niemann-Pick disease, Type C (NPC), a severely debilitating neurodegenerative lysosomal storage disorder, and current treatments primarily focus on symptomatic management, necessitating a combination therapy that targets the etiology of NPC.
Innovation Solution
Arimoclomol, an orally bioavailable small molecule, activates Transcription Factor EB (TFEB) and/or Transcription Factor E3 (TFE3) to translocate from the cytosol into the nucleus, upregulating the CLEAR network genes, including NPC1, thereby increasing lysosomal cholesterol removal and NPC1 protein production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no disease-modifying therapies are available for NPC, then only symptomatic management is possible, but disease progression cannot be halted
Solution Approach 1:
The patent uses TFEB as an intermediary transcription factor that, when activated by arimoclomol, mediates the upregulation of CLEAR network genes including NPC1. This intermediary mechanism enables disease modification by bridging the gap between the administered compound and the therapeutic effect of increased lysosomal function and cholesterol efflux
Solution Approach 2:
The patent changes the activation state parameter of TFEB from inactive to active through arimoclomol administration. This parameter change triggers a cascade effect that upregulates NPC1 expression and restores lysosomal cholesterol transport function, providing disease-modifying therapy where none previously existed
2Productivity
If TFEB is activated to upregulate CLEAR network genes, then lysosomal cholesterol removal increases, but the mechanism requires understanding of nuclear-cytosolic translocation
Solution Approach 1:
The patent extracts and utilizes the nuclear translocation property of TFEB as the key therapeutic mechanism. By administering arimoclomol that specifically promotes TFEB translocation from cytosol to nucleus, the invention isolates and exploits this specific cellular transport event to drive gene upregulation and therapeutic effect
Solution Approach 2:
The patent replaces direct mechanical or enzymatic approaches to increase lysosomal function with a molecular signaling approach. Instead of directly targeting lysosomal enzymes or transporters, the invention uses a small molecule to activate a transcription factor pathway, substituting a biochemical signaling mechanism for more direct physical or enzymatic interventions
3Quantity of substance
If arimoclomol is administered to activate TFEB, then NPC1 protein production increases, but dosing considerations must account for renal impairment
Solution Approach 1:
The patent implements dynamic dosing adjustments based on renal function status. The dosing regimen is not fixed but adapts to the patient's renal clearance capacity, with reduced doses for patients with impaired renal function. This dynamic approach maintains therapeutic efficacy while preventing toxic accumulation, enabling the therapy to be safely applied across diverse patient populations
Data Source
AI summary
The present disclosure provides methods of treating lysosomal storage disorders such as Niemann-Pick Disease, Type-C, by administering a therapeutically effective amount of arimoclomol. The present disclosure further provides methods of removing lysosomal cholesterol by administering the same.